TY - JOUR
T1 - GLP-1 receptor signaling increases PCSK1 and β cell features in human α cells
AU - Saikia, Mridusmita
AU - Holter, Marlena M.
AU - Donahue, Leanne R.
AU - Lee, Isaac S.
AU - Zheng, Qiaonan C.
AU - Wise, Journey L.
AU - Todero, Jenna E.
AU - Phuong, Daryl J.
AU - Garibay, Darline
AU - Coch, Reilly
AU - Sloop, Kyle W.
AU - Garcia-Ocana, Adolfo
AU - Danko, Charles G.
AU - Cummings, Bethany P.
N1 - Publisher Copyright:
© 2021, Saikia et al. This is an open access article published under the terms of the Creative Commons Attribution 4.0 International License.
PY - 2021/2/8
Y1 - 2021/2/8
N2 - Glucagon-like peptide-1 (GLP-1) is an incretin hormone that potentiates glucose-stimulated insulin secretion. GLP-1 is classically produced by gut L cells; however, under certain circumstances α cells can express the prohormone convertase required for proglucagon processing to GLP-1, prohormone convertase 1/3 (PC1/3), and can produce GLP-1. However, the mechanisms through which this occurs are poorly defined. Understanding the mechanisms by which α cell PC1/3 expression can be activated may reveal new targets for diabetes treatment. Here, we demonstrate that the GLP-1 receptor (GLP-1R) agonist, liraglutide, increased α cell GLP-1 expression in a β cell GLP-1R-dependent manner. We demonstrate that this effect of liraglutide was translationally relevant in human islets through application of a new scRNA-seq technology, DART-Seq. We found that the effect of liraglutide to increase α cell PC1/3 mRNA expression occurred in a subcluster of α cells and was associated with increased expression of other β cell-like genes, which we confirmed by IHC. Finally, we found that the effect of liraglutide to increase bihormonal insulin+ glucagon+ cells was mediated by the β cell GLP-1R in mice. Together, our data validate a high-sensitivity method for scRNA-seq in human islets and identify a potentially novel GLP-1-mediated pathway regulating human α cell function.
AB - Glucagon-like peptide-1 (GLP-1) is an incretin hormone that potentiates glucose-stimulated insulin secretion. GLP-1 is classically produced by gut L cells; however, under certain circumstances α cells can express the prohormone convertase required for proglucagon processing to GLP-1, prohormone convertase 1/3 (PC1/3), and can produce GLP-1. However, the mechanisms through which this occurs are poorly defined. Understanding the mechanisms by which α cell PC1/3 expression can be activated may reveal new targets for diabetes treatment. Here, we demonstrate that the GLP-1 receptor (GLP-1R) agonist, liraglutide, increased α cell GLP-1 expression in a β cell GLP-1R-dependent manner. We demonstrate that this effect of liraglutide was translationally relevant in human islets through application of a new scRNA-seq technology, DART-Seq. We found that the effect of liraglutide to increase α cell PC1/3 mRNA expression occurred in a subcluster of α cells and was associated with increased expression of other β cell-like genes, which we confirmed by IHC. Finally, we found that the effect of liraglutide to increase bihormonal insulin+ glucagon+ cells was mediated by the β cell GLP-1R in mice. Together, our data validate a high-sensitivity method for scRNA-seq in human islets and identify a potentially novel GLP-1-mediated pathway regulating human α cell function.
UR - http://www.scopus.com/inward/record.url?scp=85101211816&partnerID=8YFLogxK
U2 - 10.1172/JCI.INSIGHT.141851
DO - 10.1172/JCI.INSIGHT.141851
M3 - Article
C2 - 33554958
AN - SCOPUS:85101211816
SN - 2379-3708
VL - 6
JO - JCI insight
JF - JCI insight
IS - 3
M1 - e141851
ER -